Aaron Logan, MD, PhD, MPhil
LightNews LightNews
banner
hemedoc.bsky.social
Aaron Logan, MD, PhD, MPhil
@hemedoc.bsky.social
620 followers 110 following 410 posts
Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, HLH, MRD, post-HCT relapse, GVHD, & immune recon. Photos (Instagram): pyknosis
Posts Replies Media Videos
hemedoc.bsky.social
#ASH25 #bmtsm Jimenez: use of <7/8 MMUD improves access to donors in ethnically diverse pts (essentially 100% will be able to have a donor). The OPTIMIZE study (successor to ACCESS study) will determine how these results hold up while hopefully reducing risks associated with standard dose PTCY.
December 8, 2025 at 9:05 PM
hemedoc.bsky.social
#ASH25 #bmtsm Jimenez: most commonly mismatched HLA locus A>DR>B>C. 1yr OS 79% w 7/8, 86% <7/8 (not sig). All secondary GVHD and NRM outcomes were not sig diff w <7/8. Primary graft failure incidence higher with <7/8 (4/85) vs 7/8 (4/183).
December 8, 2025 at 9:01 PM
hemedoc.bsky.social
#ASH25 #bmtsm Jimenez: on @nmdp-org.bsky.social ACCESS all MMUDs were <=35yo and recip couldn’t have DSAs w MFI >3000. N=183 7/8, 85 <7/8. Most RIC for acute leukemia. More ethnic diversity in <7/8 group.
December 8, 2025 at 8:55 PM
hemedoc.bsky.social
#ASH25 #bmtsm Jimenez: @nmdp-org.bsky.social ACCESS study analysis of <=6/8 cw 7/8 MMUD.
December 8, 2025 at 8:53 PM
hemedoc.bsky.social
#ASH25 #bmtsm Kim: of those with cGVHD 54% steroid refractory, 96% of whom recd Rux and few went on to need later lines of therapy. 2yr OS 85% with Haplo, 82% MUD, 77% MMUD. NRM 7-10% for Haplo/MUD, 16% with MMUD.
December 8, 2025 at 8:48 PM
hemedoc.bsky.social
#ASH25 #bmtsm Kim: Haplo (201), MMUD (98), MUD (41) recd PTCY. Most haplos were MAC, most (M)MUD were RIC. 15.6% overall incidence of cGVHD, 41% mod-sev cGVHD. Of those w cGVHD 3% developed scleroderma, 2% joint contractures, 3% BOS.
December 8, 2025 at 8:44 PM
hemedoc.bsky.social
#ASH25 #bmtsm Kim: PTCy reduces incidence of fibrotic skin GVHD. Single center City of Hope analysis. Includes Haplo, (M)MUD. Excluded relapsed pts and anyone exposed to ATG.
December 8, 2025 at 8:37 PM
hemedoc.bsky.social
#ASH25 #bmtsm Soiffer: question afterward whether decreased mortality with cryo was due to increased infections or toxicity. “Yeah, something like that…” was his response. Only Dr Soiffer can get away with that. 😂
December 8, 2025 at 8:33 PM
hemedoc.bsky.social
#ASH25 #bmtsm Soiffer: in discussion there are likely significant differences from center to center wrt use of cryo grafts. Some freeze 100%, some freeze a small minority. (We only freeze if logistically needed.)
December 8, 2025 at 8:29 PM
hemedoc.bsky.social
#ASH25 #bmtsm Soiffer: although cGVHD reduced overall, this benefit of cryo was not seen in pts getting PTCy. Given higher OS in spite of lower GRFS with cryo, fresh grafts remain the preferred standard (but still reasonable when logistically useful).
December 8, 2025 at 8:27 PM
hemedoc.bsky.social
#ASH25 #bmtsm Soiffer: GRFS higher with cryo BUT OS lower (62.5 v 65.6%) vs fresh.
December 8, 2025 at 8:25 PM
hemedoc.bsky.social
#ASH25 #bmtsm Soiffer: N=4644 cryo’d allografts 2019-2022 for AML/MDS/ALL. With cryo, higher g2-4 aGVHD and lower cGVHD. Slower engraftment with cryo.
December 8, 2025 at 8:22 PM
hemedoc.bsky.social
#ASH25 #bmtsm Soiffer: @cibmtr.bsky.social analysis of outcomes with cryopreserved PBSC grafts. Single center DFCI data suggested decreased cGVHD with cryo products.
December 8, 2025 at 8:18 PM
hemedoc.bsky.social
#ASH25 #bmtsm Srour: ORCA-Q 1yr OS 87-94%, GRFS 77-79%. Better T cell recon wo Tac even though currently no signs of significantly increased GVHD in that arm.
December 8, 2025 at 8:12 PM
hemedoc.bsky.social
#ASH25 #bmtsm Srour: 1 engraftment failure out of 44. Very low rates of aGVHD. Too early for good estimation of cGVHD. Arm wo Tac had significantly lower risk of infxns (not randomized comparison). RFS 87-88% at 1yr.
December 8, 2025 at 8:09 PM
hemedoc.bsky.social
#ASH25 #bmtsm Srour: ORCA-Q in MAC allo, here reporting Tac free and single agent Tac ppx arms with 8/8 matched sib/URD. Cond with FBT or TBI.
December 8, 2025 at 8:06 PM
hemedoc.bsky.social
#ASH25 #bmtsm Munshi: @cibmtr.bsky.social PTCy vs CNI/MTX +/- ATG conclusions.
December 8, 2025 at 7:56 PM
hemedoc.bsky.social
#ASH25 #bmtsm Munshi: ATG far more commonly used with MUD vs Sib. 2yr GRFS 40% with PTCy vs 26% CNI/MTX/ATG, 17.5% wo ATG. In MVA PTCy assoc with higher GRFS, lower a/cGVHD. Higher DFS with PTCy.
December 8, 2025 at 7:54 PM
hemedoc.bsky.social
#ASH25 #bmtsm Munshi: retrospective @cibmtr.bsky.social analysis of MAC allo with PTCy vs Tac/MTX +/- ATG for matched sib/URD. Tac/MTX still most commonly used GVHD ppx in US for MAC allo. Primary endpt 2yr GRFS. N=8272
December 8, 2025 at 7:50 PM
Reposted by Aaron Logan, MD, PhD, MPhil
drmiguelperales.bsky.social
7 @astct.bsky.social Presidents walk into a bar …. Rob Negrin, Pavan Reddy, Brenda Sandmaier, Corey Cutler, Armand Keating, & Rob Soiffer #ash25
December 8, 2025 at 4:46 AM
hemedoc.bsky.social
#ASH25 #leusm DiNofia: CART019 favorable option for CNS relapse and appears far superior to chemo +/- Blin.
December 7, 2025 at 10:52 PM
hemedoc.bsky.social
#ASH25 #leusm DiNofia: 2yr EFS/OS 85/90%. Good expansion in spite of majority not having marrow disease. 6 relapses. Very low rates of high gr CRS/ICANS.
December 7, 2025 at 10:51 PM
hemedoc.bsky.social
#ASH25 #leusm DiNofia: CART (CTL019=Tisa) as 1st therapy for CNS relapse in peds B-ALL. On AALL1331 addition of Blin did not help those with CNS relapse, instigating need to find better options. N=43, 91% first relapse, 84 isolated CNS relapse, 16% CNS+BM. 23% prior Blin, 7% prior allo. ORR 100%.
December 7, 2025 at 10:47 PM
hemedoc.bsky.social
#ASH25 #leusm Wang: CRS in 45% but almost all gr1-2. Neurotox (no ICANS) in 15%, all gr1-2. ORR in dose escalation 50%. At target dose >=60mg ORR 75-92%. Small number w prior Blin treatment responded.
December 7, 2025 at 10:40 PM
hemedoc.bsky.social
#ASH25 #leusm Wang: n=75 tested w MK1045, median age 46. Median f-up 15.8mos. Most common reason for discontinuation was relapse. No dc due to AE.
December 7, 2025 at 10:35 PM